Inder Kaul News Today

The investigational antipsychotic KarXT is effective in reducing positive and negative symptoms of schizophrenia, with a favorable side-effect profile in the pivotal EMERGENT-2 trial.

In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group.

BOSTON--(BUSINESS WIRE)--Dec 14, 2023--

In a phase 3 EMERGENT-2 trial, the study found 55% of participants with schizophrenia taking xanomeline-trospium had a ≥30% improvement from baseline to week 5, compared to the placebo group.